MARKET

LEXX

LEXX

Lexaria Bioscience Corp
NASDAQ
0.7183
-0.0067
-0.92%
Opening 13:17 02/09 EST
OPEN
0.7300
PREV CLOSE
0.7250
HIGH
0.7473
LOW
0.6920
VOLUME
65.55K
TURNOVER
--
52 WEEK HIGH
1.911
52 WEEK LOW
0.4600
MARKET CAP
17.88M
P/E (TTM)
-1.2507
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LEXX last week (0202-0206)?
Weekly Report · 10h ago
Lexaria Bioscience Faces Nasdaq Delisting Risk Over Minimum Bid Price Compliance
Reuters · 2d ago
Lexaria’s Oral Liraglutide Shows Comparable Performance and Fewer Side Effects in Human Study
TipRanks · 4d ago
Lexaria announces final results from GLP-1-H25-5 study
TipRanks · 4d ago
Lexaria Bioscience Results From Human Pilot Study, Comparing DehydraTECH-liraglutide Capsules To Injected Saxenda Branded Liraglutide, Achieves 22.7% Reduction In Adverse Events With DHT-LIR As Compared To SAX-LIR
Benzinga · 4d ago
Lexaria Bioscience Reports Positive Results for Oral Liraglutide in Human Pilot Study
Reuters · 4d ago
Weekly Report: what happened at LEXX last week (0126-0130)?
Weekly Report · 02/02 09:08
Lexaria Bioscience Shareholders Endorse Directors and Auditors
TipRanks · 01/28 19:17
More
About LEXX
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

Webull offers Lexaria Bioscience Corp stock information, including NASDAQ: LEXX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LEXX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LEXX stock methods without spending real money on the virtual paper trading platform.